Mesoblast Limited Class Action Lawsuit - MESO

(1) comparative analyses between Mesoblast’s Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

In order to be eligible to join the MESO class action lawsuit, you must have incurred a loss on shares of Mesoblast purchased during the class period listed above.

If you suffered a loss in Mesoblast during the relevant time frame or pursuant to the relevant offering(s), you have until December 7, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.